

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and d⦠read more
Healthcare
Biotechnology
42 years
USD
Exclusive to Premium users
$3.41
Price-0.29%
-$0.01
$116.019m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-33.3%
3y CAGR-25.0%
5y CAGR-$10.074m
+7.8%
1y CAGR-2.4%
3y CAGR+5.2%
5y CAGR-$0.30
+11.8%
1y CAGR+0.9%
3y CAGR+7.9%
5y CAGR$13.224m
$14.865m
Assets$1.641m
Liabilities$184k
Debt1.2%
-
Debt to EBITDA-$7.117m
+0.8%
1y CAGR-5.0%
3y CAGR-2.7%
5y CAGR